Science Current Events | Science News |

FDG-PET Imaging Clearly Predicts Lung Cancer Patients' Response to Chemotherapy

May 10, 2007

Repeating Molecular Imaging Studies Provides Valuable Information for Better Patient Care, Say Researchers in May Journal of Nuclear Medicine

RESTON, Va.—An earlier indication of whether chemotherapy benefits non-small cell lung cancer patients—provided by positron emission tomography (PET) imaging—can guide doctors in offering them better care, according to researchers in the May Journal of Nuclear Medicine.

"Our study demonstrates that patients who respond to chemotherapy can be identified early in the course of their treatment, and these patients will generally exhibit prolonged overall survival," explained Claude Nahmias, professor of radiology and medicine at the University of Tennessee Medical Center in Knoxville. "Although we studied a relatively small number of patients—and our results should be interpreted with caution—it is clear that a repeat PET study with the radiotracer fluorodeoxyglucose (FDG) at the end of the first cycle of chemotherapy would allow the identification of those patients for whom the therapy was futile," he said. "The ability to provide an early indication of therapeutic response has the potential to improve patient care by identifying those patients who do not benefit from their current treatment," explained Nahmias. "Patients would benefit from either having chemotherapy and its associated toxic side effects stopped or going on to a different, and hopefully more adequate, therapeutic approach," added the co-author of "Time Course of Early Response to Chemotherapy in Non-Small Cell Lung Cancer Patients With 18F-FDG PET/CT."

Non-small cell lung cancer is the most common type of lung cancer, usually growing and spreading more slowly than small cell lung cancer. -Lung cancer is the second most common cancer and the most common cause of cancer-related death in both men and women in the United States. In 2007, about 213,380 new cases of lung cancer (both small cell and non-small cell) are expected in the United States, and about 160,390 people will die of this disease. For most patients with non-small cell lung cancer, current treatments do not cure the cancer.

"With non-small cell lung cancer—since the relatively modest increase in survival must be balanced against the toxicity of the chemotherapeutic treatment—the case for monitoring therapeutic response is especially compelling," said Nahmias. "To assess the response to chemotherapy in patients with advanced non-small cell lung cancer, all of the studies published thus far have evaluated the patients at one, or at most two, time points after the initiation of chemotherapy," said Nahmias. "In our study, we evaluated 15 patients weekly—for seven weeks—as they started their chemotherapy regiment. In spite of the persuasive findings of several studies investigating PET for monitoring response to cancer therapy, until now no published reports have clearly demonstrated that PET results were used to alter treatment," he noted.

PET is a powerful molecular imaging procedure that noninvasively demonstrates the function of organs and other tissues. When PET is used to image cancer, a radiopharmaceutical (such as FDG, which includes both a sugar and a radionuclide) is injected into a patient. Cancer cells metabolize sugar at higher rates than normal cells, and the radiopharmaceutical is drawn in higher amounts to cancerous areas. PET scans show where FDG is by tracking the gamma rays given off by the radionuclide tagging the drug and producing three-dimensional images of their distribution within the body. PET scanning provides information about the body's chemistry, metabolic activity and body function.

"Our result—that PET studies one and three weeks after initiation of cancer therapy can predict success or failure of the therapy—should be validated in a larger study in which patients are enrolled with the intention of applying it in patient management," said Nahmias. He added, "I am forever grateful to all the patients who came back week after week to undergo our PET scans."

"Time Course of Early Response to Chemotherapy in Non-Small Cell Lung Cancer Patients With 18F-FDG PET/CT" appears in the May issue of the Journal of Nuclear Medicine, which is published by SNM, the world's largest molecular imaging and nuclear medicine society. Other co-authors are Wahid T. Hanna, Misty J. Long, Karl F. Hubner and David W. Townsend, departments of Medicine and Radiology, University of Tennessee, Knoxville, and Lindi M. Wahl, Department of Applied Mathematics, University of Western Ontario, London, Canada.

Society of Nuclear Medicine

Related Lung Cancer Current Events and Lung Cancer News Articles

Subsolid lung nodules pose greater cancer risk to women than men
Women with a certain type of lung nodule visible on lung cancer screening CT exams face a higher risk of lung cancer than men with similar nodules, according to a new study being presented next week at the annual meeting of the Radiological Society of North America (RSNA).

Tumor-suppressor p53 regulates protein that stifles immune attack on cancer
A crucial tumor-thwarting gene protects an immune attack against lung cancer by blocking the key to an off switch on T cells, the customized warriors of the immune system, a team led by researchers at The University of Texas MD Anderson Cancer Center reports in the Journal of the National Cancer Institute.

Blood sample new way of detecting cancer
A new RNA test of blood platelets can be used to detect, classify and pinpoint the location of cancer by analysing a sample equivalent to one drop of blood.

Sorafenib modestly increases progression-free survival
Sorafenib, a tyrosine kinase inhibitor (TKI) targeting the receptors for vascular endothelial growth factor, platelet derived growth factor, and mast/stem cell growth factor, modestly increases progression-free survival (PFS), time to progression, and disease control rate in non-small cell lung cancer (NSCLC) patients who have relapsed or failed two or three previous treatment regimens.

Liquid biopsy of cerebrospinal fluid for more effective policing of brain tumors
Reported in the journal Nature Communications, the Vall d'Hebron Institute of OncologyÂ's (VHIO) Gene Expression and Cancer Group, led by Joan Seoane, has pioneered research evidencing the use of cerebrospinal fluid (CSF) as liquid biopsy for the potential prognosis, treatment, identification and tracking of brain tumor genomic alterations not only in real time but over time.

Simple test predicts response to chemotherapy in lung cancer patients
November is Lung Cancer Awareness Month, highlighting the number one cause of cancer-related death in North America.

Tumor RNA in platelets may diagnose and classify cancer, identify treatment strategies
Analysis of tumor RNA carried in platelets - blood components best known for their role in clotting - may prove to be more useful than other "liquid biopsy" technologies for diagnosing cancer and determining its primary location and potential therapeutic approaches.

WSU researchers develop natural protein cage for improved cancer drug delivery
Washington State University researchers have developed a unique, tiny protein cage to deliver nasty chemotherapy chemicals directly to cancer cells. Direct delivery could improve treatment and lessen what can be horrendous side effects from toxic drugs.

A new way to starve lung cancer?
Scientists have identified a new way to stop the growth of lung cancer cells, by blocking their ability to use alternative sources of nutrition.

Patients undergoing lung cancer screening experience elevated levels of distress
Low-dose computed tomography (LDCT) lung cancer screening is recommended to screen patients with an increased risk of developing lung cancer, but little research regarding the emotional toll of screening has been conducted.
More Lung Cancer Current Events and Lung Cancer News Articles

Non-Small Cell Lung Cancer: Across the Continuum of Care

Non-Small Cell Lung Cancer: Across the Continuum of Care
by Asante Communications, LLC

This Clinical Resource Tool is structured around consensus statements developed by the Non-Small Cell Lung Cancer (NSCLC) Working Group, a panel of oncologists with particular expertise in the multidimensional care of patients with advanced lung cancer. Using a modified Delphi process, the NSCLC Working Group has consolidated published evidence and expert clinical experience on critical issues pertaining to the comprehensive assessment of patients with advanced NSCLC, formulation of appropriate treatment regimens, implementation of maintenance therapy, and therapeutic alliances among pathologists, oncologists, and pulmonologists. The consensus statements and accompanying resources are intended as a practical companion to current guidelines, helping clinicians individualize best-practice...

Living with Lung Cancer--My Journey

Living with Lung Cancer--My Journey
by Thomas E. Cappiello (Author)

On October 5 2007, Thomas Cappiello was diagnosed with inoperable Stage IIIA locally-advanced adenocarcinoma (Non-Small Cell Lung Cancer), an incurable disease. This book is the inspirational story of how he beat the odds and survived and thrived in the face of this devastating illness. This book is for patients and caregivers who want to know what life is like after getting a cancer diagnosis. The story is about overcoming the emotional turmoil and devastation of a cancer diagnosis, dealing with the disease, and making choices. Most of all, it's about living a full life each day. Cancer patients suddenly realize that time is a precious gift from God and there is no time to waste. By telling his story Cappiello seeks to inspire cancer patients to fight hard and live, with whatever time...

How to Survive Lung Cancer - A Practical 12-Step Plan

How to Survive Lung Cancer - A Practical 12-Step Plan
by Michael Lloyd (Author)

Written by a lung cancer survivor who understands what it takes to beat the odds, this book offers unparalleled hope and direction for anyone facing this illness. It is filled with specific exercises and techniques to promote healing and reverse side effects by taking a pro-active approach in helping to restore your mind, body and spirit to an optimum state of health. Endorsed by a Lung Cancer Specialist and Associate Professor at Harvard Medical School, this book combines what the doctors tell you with critical information they don't tell you. Visit for chapter summaries.

Bonnie J. Addario Navigating Lung Cancer 360 Degrees of Hope

Bonnie J. Addario Navigating Lung Cancer 360 Degrees of Hope
by Bonnie J. Addario (Author), MD, PhD, Shane P. Dormady (Author), RN, MSN, CPHQ, Eileen Johnson (Author), RN, MBA, Alicia Sable-Hunt (Author), Danielle Hicks (Editor), MD, Paul Hesketh (Editor), MD, Robert Sinha (Editor), MD, PhD, D. Ross Camidge (Editor), MD, Elizabeth A. David (Editor), MD, Lisa Boohar (Editor), MD, David R. Gandara (Editor), PhD, Guneet Walia (Editor), Inc., Sheila Von Driska?White Space (Editor)

Navigating Lung Cancer 360 Degrees of Hope is the most comprehensive guidebook for surviving lung cancer. Inside each latest edition you will get the most up-to-date navigation tools on the diagnosis process, lung cancer staging, treatment options, clinical trials, living with lung cancer, financing your care, hope for surviving lung cancer, and more. Written by survivor Bonnie J. Addario and the leading experts in lung cancer with one goal: to turn lung cancer into a manageable and survival disease.

Lung Cancer Causes, Symptoms,  Stages & Treatment Guide: Cure Lung Cancer With  A Positive Outlook

Lung Cancer Causes, Symptoms, Stages & Treatment Guide: Cure Lung Cancer With A Positive Outlook
by Danielle Dixon

This book contains proven steps and strategies on how to prevent, treat and fight cancer.

Cancer has long been closely associated with death, low quality of life, and financial difficulties. With all the complications it causes, lives it takes, and people it subjects to suffering, cancer is definitely a difficult disease.

Lung cancer is one of the leading causes of cancer deaths worldwide. Different risk factors have been attributed to its development- with genetics and environmental influences playing a major role. The diversity of its causes makes its treatment all the more difficult, which makes identification of causes essential to its management. The recognition of symptoms and diagnosis early in the course of the disease most frequently leads to good...

Lung Cancer: A Guide to Diagnosis and Treatment

Lung Cancer: A Guide to Diagnosis and Treatment
by Walter J. Scott MD (Author)

What is my prognosis? What are my treatment options? Which therapies would be the most effective for my stage of lung cancer? These and other frequently asked questions are addressed in this crucial reference designed to help patients educate themselves and obtain the best possible treatments. The completely revised second edition has been updated to include a discussion of the movement towards customized chemotherapy; treatment options for early-stage lung cancer including minimally invasive surgery; and the most promising treatments, among them multimodality therapy—a combination of surgery, chemotherapy, and radiation. Dr. Scott also surveys tests for early detection of lung cancer, talks about the importance of cancer staging, examines alternative treatments, and offers advice on...

Lung Cancer

Lung Cancer
by Jack A. Roth (Editor), Waun Ki Hong (Editor), Ritsuko U. Komaki (Editor)

The best and most concise single source for state-of-the-art diagnosis and treatment of lung cancer –newly revised, updated, and expanded.

Lung cancer has long been the number-one cause of death from cancer every year and the third most frequently diagnosed after breast and prostate cancers. In 2010, about 15% of all cancer diagnoses and 30% of all cancer deaths were due to lung cancer. Needless to say, there is a great need for more rapid advancements in diagnosis and treatment of this devastating disease. Here is the comprehensively revised, updated, and expanded edition of the well-established, evidence-based reference book that deals with the most recent advances in lung cancer prevention, screening, diagnosis, research, and treatment for the clinician. Edited and...

You Can Beat Lung Cancer: Using Alternative/Integrative Interventions

You Can Beat Lung Cancer: Using Alternative/Integrative Interventions
by Carl O. Helvie (Author)

Can you overcome lung cancer without harsh chemicals, surgery and debilitation? Are alternative interventions effective? Why do conventional physicians not use them? Can you prevent cancer recurrences and live into old age without chronic diseases and prescribed medications? This book answers these and other questions.

This is one of the most comprehensive books available on alternative treatments for lung cancer. It explains the treatments used successfully by a health professional/cancer survivor of 36 years and by some of the leading medical and health practitioners currently in the field. G. Edward Griffin, Author of World Without Cancer, The Politics of Cancer Therapy, and other books and films. Recipient of the Telly Award for Excellence in Television Production. President of...

Cancer: Coping With Cancer: How To Cope When A Loved One Has Cancer Without Any Grieving (Cancer,Coping With Cancer,Cancer Books,Breast Cancer,Colon Cancer,Lung ... Cure,Prostate Cancer,Cancer Prevention)

Cancer: Coping With Cancer: How To Cope When A Loved One Has Cancer Without Any Grieving (Cancer,Coping With Cancer,Cancer Books,Breast Cancer,Colon Cancer,Lung ... Cure,Prostate Cancer,Cancer Prevention)

Find Out How To Cope When A Loved One Has Cancer Now
Get This Bestseller For Only $2.99 Regularly priced
at $4.99. Read on your PC, Mac, smart phone, tablet or Kindle device.

You’re about to discover how to cope with having a loved one who is suffering with cancer and how you can help their journey be a positive one. Coping with cancer is tough and this book has everything you need to feel confident that you can handle every responsibility that comes with taking care of a loved one with cancer. Cancer is a very tough time that leaves every person involved going through many emotions. This book will help relieve and control those thoughts and feelings.

Here Is A Preview Of What You'll Learn...
How To Take On Role As A Caregiver How To Care...

Lung Cancer: Diagnosis and Management

Lung Cancer: Diagnosis and Management
by NetCE

The purpose of this course is to address the various aspects of diagnosis, treatment, disease management and appropriate patient care for healthcare professionals caring for patients with lung cancer. In addition, members of the public may use this course to enhance their personal knowledge of the subject matter presented.

Upon completion of this course, you should be able to:

1. Discuss the risk factors and incidence of lung cancer.
2. Explain the pathophysiology of lung cancer.
3. Identify the signs and symptoms of lung cancer.
4. Discuss the various tests used to diagnose lung cancer.
5. Describe the lung cancer classification and staging system.
6. Discuss the treatment options available to the patient with lung cancer, including...

© 2015